EVALUATING FAMILY HISTORY QUESTIONNAIRE VERSUS FAMILY PEDIGREE INTERVIEW FOR GENETIC DISORDERS IN PRIMARY HEALTH CARE, QASSIM REGION, SAUDI ARABIA
Journal Title: European Journal of Biomedical and Pharmaceutical Sciences - Year 2017, Vol 4, Issue 8
Abstract
Introduction: The use of family history as screening tool (pedigree or questionnaire) has been shown to increase the likelihood of detecting a patient at high risk of developing an inherited medical condition by 20% compared with medical record review alone. Objectives: 1.To assess the ability of the current used Family History Questionnaire, to identify genetic risk in the study population 2. assess the ability of family pedigree interview with patient, to identify genetic risk and compare the ability to identify genetic risk between family pedigree interview and currently used questionnaire. Methodology: Institutional based descriptive study, compared a random sample of reviewer currently used family history questionnaire in Primary Health Care (PHC) with standardized family history, pedigree questionnaire for evaluating risk of common genetic diseases among Qassim population. Same participant fills both questionnaire during the period from March 2015 to August 2015 among 289 participants. Results: currently used family file folders revealed that nearly 61.9% of total files had a family history of diabetes and 53% had a history of hypertension also 15.6% had asthma history. With the the involvement of Family Pedigree interview revealed that history of Genetic diseases 5.9% and Down syndrome was 5.9% and diabetes was 51.9%. There was significant difference was noticed with family pedigree interview. In comparison with regularly used family history questionnaire in primary care unit our study genetic family history questionnaire was succeeded in measuring familial genetic risk factors in higher percent for non-insulin dependent diabetes, cancer (colon breast, prostate, varies, etc.), hypertension and coronary heart diseases. Conclusions: Based on the study results, the currently used family record folders which were available in PHC not focussed on genetic diseases family history only focused on few selected diseases. Good evaluation of familial genetic risk is crucial to assess the potentiality of patient to get diseases by assessing genetic risk factors and in that order the physician may find preventive measures to decrease his patient disease potentiality in terms of reduction of cost expenditure, premature deaths and quality of productive life .
Authors and Affiliations
Dr. Mohammed Al Alfi
Keywords
Related Articles
- EP ID EP628944
- DOI -
- Views 173
- Downloads 0
ANTIFUNGAL POTENTIAL OF QUERCUS INFECTORIA GALLS AGAINST CANDIDA ALBICANS-AN INVITRO STUDY
The promising potential of antimicrobial plant derived substances has attracted the attention of pharmaceutical and scientific communities during the last few years. The primary benefit of plant derived medicines is that...
EXPERIENCE OF UNDERGRADUATE MEDICAL STUDENTS IN COMMUNITY FIELD TRAINING IN QASSIM, SAUDI ARABIA
Background: A field training community based course was established to achieve the college‟s mission of imparting community oriented education. The main training locations were government primary health care (PHC) center...
LEVELS OF EOSINOPHIL AND MICROPHAGE-SECRETED CYTOKINES IN PLASMODIA- INFECTED CHILDREN IN PORT HARCOURT, NIGERIA
Infection with plasmodia and the attendant complications, including hyper-secretion of pro-inflammatory cytokines, remain a leading cause of high morbidities and mortalities among children in African countries and moreso...
PRESENCE OF SEROTONERGIC 5HT4-TYPE RECEPTORS IN BROILER’S SMALL INTESTINE
The aim of the present study was to try to determine the possible distribution of 5-HT4 receptors in small intestine of broilers (duodenum, jejunum and ileum). The disturbances of bowel function are common in broilers an...
IN VITRO BIOLOGICAL ACTIVITY ASSESSMENT OF RHEPO PHARMACEUTICAL FORMULATIONS FOR BATCH RELEASE
Background: Recombinant human erythropoietin (rhEPO) is the pharmaceutical form of erythropoietin (EPO), used for the treatment of chronic kidney disease and cancer-associated anemia, act as a growth proliferation factor...